Fig. 1 · Structure

Documents & Downloads

ENMD-2076

Cat. No. A10352 CAS 934353-76-1

Aurora A / FLT3 Inhibitor

ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Free-base ENMD-2076 reduced Aurora phosphorylation in nocodazole-synchronized HCC1806 breast-cancer cells after a 2-hour exposure at 0.5–2.5 μmol/L. This cellular result supports Aurora-pathway inhibition but does not define purified-enzyme potency or exclusive target selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
FLT3 IC50 1.86nM
RET IC50 10.4nM
AuroraA IC50 14nM
VEGFR3/FLT4 IC50 15.9nM
Src IC50 20.2nM
NTRK1/TRKA IC50 24.2nM
CSF-1R/c-Fms IC50 24.8nM
LCK IC50 43.7nM
FAK IC50 54.9nM
PDGFRα IC50 56.4nM
VEGFR2/KDR IC50 58.2nM
BLK IC50 69.4nM
FGFR2 IC50 70.8nM
YES1 IC50 78.4nM
Abl1(T315I) IC50 81.3nM
FGFR1 IC50 92.7nM
Fyn IC50 112nM
JAK2 IC50 120nM
Kit IC50 120nM
AuroraB IC50 350nM

20 targets · Scroll to view more

Cellular Effect

Cell Line Activity Value Description Reference
MDA-MB-231 IC50 0.48 μM Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 32058239]
PC-3 IC50 0.67 μM Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 32058239]

ENMD-2076 Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of ENMD-2076 from 2 published references. In vitro models include HCC1806 human TNBC cells, with nocodazole synchronization. In vivo models include three TP53-mutated human TNBC PDX models in female athymic nude mice.

ENMD-2076 In Vitro Studies

In a 29-line breast-cancer panel, free-base ENMD-2076 produced 96-hour SRB IC50 values of 0.25–16.1 μmol/L. Responses varied within TNBC: sensitive and resistant lines were both present. These protein-accumulation endpoints should not be read as direct measurements of cell death. [1]

Free-base ENMD-2076 growth inhibition across breast-cancer cell lines

Cell-based study · Panel of 29 human breast-cancer cell lines, including TNBC, ER-positive and HER2-amplified subtypes [1]

The 96-hour SRB response varied substantially across cell lines. TNBC was enriched among sensitive lines, but included resistant models; subtype alone did not ensure sensitivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SRB-derived inhibition of cellular protein accumulation across the 29-line panelIC50 0.25–16.1 μmol/L[1]
Lines below the authors’ sensitivity thresholdclassification 8 sensitive lines (IC50 < 1 μmol/L); 11 resistant lines (IC50 > 3 μmol/L)[1]
Examples demonstrating response variation within TNBCIC50 HCC1187: 0.25 μmol/L; MDA-MB-468: 0.46 μmol/L; HCC1806: 3.12 μmol/L; HCC1937: 5.83 μmol/L[1]

Literature-Reported Treatment Conditions

Treatment concentration
0–20 μmol/L concentration series
Exposure duration
96 hours for the adopted screen
Method
SRB absorbance assay at 565 nm; no-drug concentration included.
Vehicle
DMSO stock (10 mmol/L); final DMSO fraction and whether no-drug wells were solvent-matched not specified in the retrieved methods.
Reported limits
No per-line raw replicate data or numerical uncertainty assigned here. SRB measures protein accumulation, not direct cell death.
Methods and source locations

Compound reported in the paper: ENMD-2076; Compound label in the paper: ENMD-2076 free base, supplied by EntreMed

Free-base cellular evidence; findings depend on model and assay conditions.

Figure 1A-B; Results: In vitro antiproliferative activity and Correlation of ENMD-2076 sensitivity; Methods: Drugs and Evaluation of cytotoxicity

SRB-derived inhibition of cellular protein accumulation across the 29-line panel: 96-hour sulforhodamine B assay; IC50 calculated from a minimum of three experiments. — Results: In vitro antiproliferative activity; Figure 1A-B and caption; Methods: Evaluation of cytotoxicity

Lines below the authors’ sensitivity threshold: Authors’ predefined classification of the same panel; remaining lines intermediate. — Results: In vitro antiproliferative activity; Figure 1A

Examples demonstrating response variation within TNBC: Same 96-hour SRB screen; exact numbers stated in Results, not estimated from graph. — Results: Correlation of ENMD-2076 sensitivity with differentially expressed genes and pathways in TNBC; Figure 1A

Aurora phosphorylation in synchronized HCC1806 cells

Cell-based study · HCC1806 human TNBC cells, with nocodazole synchronization [1]

ENMD-2076 reduced Aurora phosphorylation in the synchronized-cell immunoblot. This is cellular pharmacodynamic evidence; it does not establish purified-enzyme potency or exclusive target selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Phosphorylated Aurora A, B and C relative to synchronized no-ENMD-2076 controlqualitative immunoblot Reduced p-Aurora A at 0.5 and 2.5 μmol/L; suppression of p-Aurora B/C most evident at 2.5 μmol/L[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 or 2.5 μmol/L ENMD-2076
Exposure duration
2 hours after 18-hour nocodazole synchronization
Method
HCC1806 synchronized with 0.5 μg/mL nocodazole before the ENMD-2076 exposure; medium-only comparators shown.
Vehicle
ENMD-2076 stock in DMSO; final DMSO fraction and explicit solvent matching not specified.
Co-treatment
Nocodazole pretreatment for cell-cycle synchronization; not an ENMD-2076 monotherapy growth assay.
Reported limits
No quantitative cellular IC50 or selectivity ratio determined in this experiment; total Aurora blots not shown in panel E.
Methods and source locations

Compound reported in the paper: ENMD-2076; Compound label in the paper: ENMD-2076 free base, supplied by EntreMed

Free-base cellular evidence; findings depend on model and assay conditions.

Figure 3E and caption; Methods: Drugs and Immunoblotting Analysis; corresponding Results

Phosphorylated Aurora A, B and C relative to synchronized no-ENMD-2076 control: Pan-phospho-Aurora immunoblot with actin loading control; nocodazole-negative and nocodazole-positive no-drug lanes included. — Figure 3E and caption; Results: Treatment with ENMD-2076 induces a G2 cell cycle arrest; Methods: Immunoblotting Analysis

ENMD-2076 In Vivo Studies

ENMD-2076 tartrate, reported at 200 mg/kg orally once daily, inhibited day-30 tumor growth in two of three TP53-mutated TNBC PDX models. CU_TNBC_004 did not show significant inhibition, despite pharmacodynamic marker changes. Significant tumor regression was not observed. The tested salt and reported doses are not assumed equivalent to the catalog free base. [2]

Initially responsive PDX tumors regrew during continued ENMD-2076 tartrate treatment. In selected tumors, Ki67 recovered while CD34 staining remained reduced, indicating that the vascular-marker response did not ensure sustained growth control. [2]

Tartrate ENMD-2076 initial response in three TNBC PDX models

Animal study · Three TP53-mutated human TNBC PDX models in female athymic nude mice [2]

At day 30, two PDX models showed significant growth inhibition and one did not. pAurA reduction occurred in both a sensitive and a resistant model; target-associated marker changes did not guarantee tumor response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Day-30 tumor growth inhibition against vehicle in the three modelsTGI CU_TNBC_002: 71.3%, p < 0.0001; CU_TNBC_005: 66.1%, p < 0.001; CU_TNBC_004: 37.0%, p > 0.05[2]
pAurA and pHH3 in CU_TNBC_005 and CU_TNBC_004 at days 4 and 30qualitative pharmacodynamic staining Decreased pAurA and increased pHH3 in both models relative to vehicle[2]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily, continuous dosing
Treatment course
30 days
Vehicle
Drug prepared as 40 mg/mL stock in water; control identified as vehicle, composition not separately specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CU_TNBC_002 tartrate treatment versus vehicle
200 mg/kg ENMD-2076 tartrate as reported; salt/free-base mass basis not clarified
Concurrent vehicle controlDay-30 TGI 71.3%, p < 0.0001; reduced growth without significant regression.[2]
CU_TNBC_005 tartrate treatment versus vehicle
200 mg/kg ENMD-2076 tartrate as reported; salt/free-base mass basis not clarified
Concurrent vehicle controlDay-30 TGI 66.1%, p < 0.001; reduced growth without significant regression.[2]
CU_TNBC_004 tartrate treatment versus vehicle
200 mg/kg ENMD-2076 tartrate as reported; salt/free-base mass basis not clarified
Concurrent vehicle controlDay-30 TGI 37.0%, p > 0.05; no statistically significant growth inhibition.[2]
CU_TNBC_002 tartrate treatment versus vehicle
Model: CU_TNBC_002 TNBC PDX
Reported limits: No conversion to catalog free base; exact animal counts per model beyond at least 10 tumors/group are not provided in the adopted text.
CU_TNBC_005 tartrate treatment versus vehicle
Model: CU_TNBC_005 TNBC PDX
Reported limits: No conversion to catalog free base; exact animal counts per model beyond at least 10 tumors/group are not provided in the adopted text.
CU_TNBC_004 tartrate treatment versus vehicle
Model: CU_TNBC_004 TNBC PDX
Reported limits: No conversion to catalog free base; exact animal counts per model beyond at least 10 tumors/group are not provided in the adopted text.
Methods and source locations

Compound reported in the paper: ENMD-2076; Compound label in the paper: ENMD-2076 tartrate salt, supplied by CASI

Related-form animal evidence only: tested material was tartrate. Reported mg/kg doses are reproduced as written; mass basis was not clarified as salt versus free-base equivalent.

Figure 1A-B and caption; Methods: Drugs, In Vivo TNBC PDX Studies, Immunofluorescence, Statistical Analysis; Results: Antitumor Activity and Pharmacodynamic Effects; Discussion

Day-30 tumor growth inhibition against vehicle in the three models: TGI = 1 − (average treated tumor volume / average vehicle tumor volume); unpaired t-test with Welch correction reported. — Figure 1A and caption; Results: Antitumor Activity; Methods: In Vivo TNBC PDX Studies and Statistical Analysis

pAurA and pHH3 in CU_TNBC_005 and CU_TNBC_004 at days 4 and 30: Immunofluorescence images with DAPI; qualitative observation from original Results and Figure 1B. — Figure 1B and caption; Results: Pharmacodynamic Effects; Methods: Immunofluorescence

CU_TNBC_002 tartrate treatment versus vehicle · Methods: Drugs and In Vivo TNBC PDX Studies; Figure 1A and caption

CU_TNBC_005 tartrate treatment versus vehicle · Methods: Drugs and In Vivo TNBC PDX Studies; Figure 1A and caption

CU_TNBC_004 tartrate treatment versus vehicle · Methods: Drugs and In Vivo TNBC PDX Studies; Figure 1A and caption

Continued tartrate dosing and regrowth in initially sensitive PDX tumors

Animal study · Longitudinal continuation in initially sensitive CU_TNBC_002 and CU_TNBC_005 PDX tumors; selected tumor tissues for correlative analysis [2]

Tumors regrew during continued treatment. Ki67 recovered toward vehicle levels while CD34 staining remained reduced in selected tissues. These associations show that persistent vascular-marker changes did not ensure durable tumor control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Regrowth during continued ENMD-2076 dosing in initially responsive tumorsauthors’ acquired-resistance criterion At least doubling of tumor volume from day 30 while on treatment[2]
Ki67 and CD34 in selected initial-response and later-regrowth tissuesqualitative IHC Ki67 decreased at day 30 and returned to levels comparable to vehicle at regrowth; CD34 remained reduced[2]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily, continuous dosing
Treatment course
Continued beyond day 30 until regrowth; selected individual tumors have differing endpoint times.
Vehicle
Drug stock prepared in water; vehicle composition not separately specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CU_TNBC_002 continued tartrate treatment
200 mg/kg ENMD-2076 tartrate as reported; salt/free-base mass basis not clarified
Vehicle tumors shown for comparison; within-treated tumor comparison from day 30.Selected tumors regrew to at least twice their day-30 volume during continued treatment; Ki67 recovered while CD34 staining remained reduced.[2]
CU_TNBC_005 continued tartrate treatment
200 mg/kg ENMD-2076 tartrate as reported; salt/free-base mass basis not clarified
Vehicle tumors shown for comparison; within-treated tumor comparison from day 30.Selected tumors regrew to at least twice their day-30 volume during continued treatment; Ki67 recovered while CD34 staining remained reduced.[2]
CU_TNBC_002 continued tartrate treatment
Model: Initially sensitive CU_TNBC_002 TNBC PDX; selected individual tumors
Reported limits: No extension cohort size or uniform course inferred from selected individual curves.
CU_TNBC_005 continued tartrate treatment
Model: Initially sensitive CU_TNBC_005 TNBC PDX; selected individual tumors
Reported limits: No extension cohort size or uniform course inferred from selected individual curves.
Methods and source locations

Compound reported in the paper: ENMD-2076; Compound label in the paper: ENMD-2076 tartrate salt, supplied by CASI

Related-form animal evidence only: tested material was tartrate. Reported mg/kg doses are reproduced as written; mass basis was not clarified as salt versus free-base equivalent.

Figure 2A-D and caption; Results: ENMD-2076 Treatment to Acquired Resistance; Methods: Drugs, In Vivo TNBC PDX Studies and Immunohistochemistry

Regrowth during continued ENMD-2076 dosing in initially responsive tumors: Individual tumor curves and selected-tumor comparison; this criterion is relative to day 30, not pretreatment baseline. — Figure 2A-B and caption; Results: ENMD-2076 Treatment to Acquired Resistance

Ki67 and CD34 in selected initial-response and later-regrowth tissues: Representative IHC; correlative samples selected based on mean tumor volume to minimize necrotic tissue. At least three samples from at least two animals assessed per time point (general IHC method). — Figure 2C-D and caption; Results: ENMD-2076 Treatment to Acquired Resistance; Methods: Immunohistochemistry

CU_TNBC_002 continued tartrate treatment · Figure 2A-D and caption; Results: ENMD-2076 Treatment to Acquired Resistance; Methods: Drugs and In Vivo TNBC PDX Studies

CU_TNBC_005 continued tartrate treatment · Figure 2A-D and caption; Results: ENMD-2076 Treatment to Acquired Resistance; Methods: Drugs and In Vivo TNBC PDX Studies

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 934353-76-1
Applications Aurora A / FLT3 Inhibitor
Formula C21H25N7
Molecular Weight 375.5
SMILES
CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)/C=C/C4=CC=CC=C4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 101 mg/mL (268.99 mM)
Water 1 mg/mL (2.66 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
0.5% CMC+0.25% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

ENMD-2076 Research References

  1. [1] Jennifer R Diamond, S Gail Eckhardt, Aik Choon Tan, et al. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 23136197 DOI: 10.1158/1078-0432.ccr-12-1611 Source material
  2. [2] Anastasia A Ionkina, John J Tentler, Jihye Kim, et al. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer Frontiers in oncology (2017). PMID: 28555173 DOI: 10.3389/fonc.2017.00094 Source material

Added to your cart

View Cart Checkout
Loading...